Arvin Yang

13.4k total citations
13 papers, 402 citations indexed

About

Arvin Yang is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Arvin Yang has authored 13 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Arvin Yang's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Melanoma and MAPK Pathways (5 papers). Arvin Yang is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Melanoma and MAPK Pathways (5 papers). Arvin Yang collaborates with scholars based in United States, Italy and France. Arvin Yang's co-authors include Edmund C. Lattime, Paul B. Chapman, Jedd D. Wolchok, Claude E. Monken, Jeffrey S. Weber, Francesca Avogadri, Jianda Yuan, David Schaer, F. Stephen Hodi and Roberta Zappasodi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Current topics in microbiology and immunology.

In The Last Decade

Arvin Yang

13 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arvin Yang United States	10	254	230	104	41	25	13	402
Yasemin Virk France	3	290 1.1×	236 1.0×	118 1.1×	17 0.4×	34 1.4×	3	427
Kentaro Yuge Japan	8	250 1.0×	328 1.4×	104 1.0×	53 1.3×	15 0.6×	13	458
Jelle J. Lindenberg Netherlands	11	262 1.0×	185 0.8×	98 0.9×	26 0.6×	10 0.4×	14	373
Jayashri Mahalingam Taiwan	6	378 1.5×	313 1.4×	100 1.0×	19 0.5×	24 1.0×	10	518
Nela Klein-González Germany	7	243 1.0×	209 0.9×	110 1.1×	19 0.5×	17 0.7×	13	344
Huanle Gong China	11	423 1.7×	178 0.8×	104 1.0×	26 0.6×	22 0.9×	19	543
Rose Al Abosy United States	5	239 0.9×	226 1.0×	145 1.4×	57 1.4×	24 1.0×	8	413
Dolgor Baatar United States	9	345 1.4×	226 1.0×	114 1.1×	12 0.3×	21 0.8×	9	500
Lisa Geiselhart United States	6	276 1.1×	137 0.6×	92 0.9×	35 0.9×	11 0.4×	11	407
Tom Hofland Netherlands	9	208 0.8×	235 1.0×	97 0.9×	52 1.3×	11 0.4×	18	430

Countries citing papers authored by Arvin Yang

Since Specialization

Citations

This map shows the geographic impact of Arvin Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvin Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvin Yang more than expected).

Fields of papers citing papers by Arvin Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arvin Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvin Yang. The network helps show where Arvin Yang may publish in the future.

Co-authorship network of co-authors of Arvin Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Arvin Yang. A scholar is included among the top collaborators of Arvin Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arvin Yang. Arvin Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

O’Donnell, John C., et al.. (2020). Evolving Use of Real-World Evidence in the Regulatory Process: a Focus on Immuno-Oncology Treatment and Outcomes. Future Oncology. 17(3). 333–347. 17 indexed citations

2.

Zhao, Qihong, Anwar Murtaza, Ragini Vuppugalla, et al.. (2018). Abstract 3760: Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade. Cancer Research. 78(13_Supplement). 3760–3760. 8 indexed citations

3.

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology. 33(15_suppl). LBA1–LBA1. 7 indexed citations

4.

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology. 33(18_suppl). LBA1–LBA1. 37 indexed citations

5.

Avogadri, Francesca, Roberta Zappasodi, Arvin Yang, et al.. (2014). Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. Cancer Immunology Research. 2(5). 448–458. 36 indexed citations

6.

Chmielowski, Bartosz, Omid Hamid, David R. Minor, et al.. (2013). A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.. Journal of Clinical Oncology. 31(15_suppl). TPS9105–TPS9105. 4 indexed citations

7.

Hamid, Omid, Wen‐Jen Hwu, Jon Richards, et al.. (2012). Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.. Journal of Clinical Oncology. 30(15_suppl). 8508–8508. 11 indexed citations

8.

Avogadri, Francesca, Jianda Yuan, Arvin Yang, David Schaer, & Jedd D. Wolchok. (2010). Modulation of CTLA-4 and GITR for Cancer Immunotherapy. Current topics in microbiology and immunology. 344. 211–244. 21 indexed citations

9.

Wolchok, Jedd D., Arvin Yang, & Jeffrey S. Weber. (2010). Immune Regulatory Antibodies. The Cancer Journal. 16(4). 311–317. 21 indexed citations

10.

Yang, Arvin & Paul B. Chapman. (2009). The History and Future of Chemotherapy for Melanoma. Hematology/Oncology Clinics of North America. 23(3). 583–597. 65 indexed citations

11.

Yang, Arvin & Edmund C. Lattime. (2003). Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.. PubMed. 63(9). 2150–7. 134 indexed citations

12.

Yang, Arvin, Claude E. Monken, & Edmund C. Lattime. (2003). Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen.. PubMed. 63(20). 6956–61. 30 indexed citations

13.

Poretz, R. D., Arvin Yang, Wenbin Deng, & Paul Manowitz. (2000). The interaction of lead exposure and arylsulfatase A genotype affects sulfatide catabolism in human fibroblasts.. PubMed. 21(3). 379–87. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact